2D Nanozymes Modulate Gut Microbiota and T-Cell Differentiation for Inflammatory Bowel Disease Management.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37897434.
- Also identified by DOI 10.1002/adhm.202302576.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Intestinal commensal microbiota dysbiosis and immune dysfunction are significant exacerbating factors in inflammatory bowel disease (IBD). To address these problems, Pluronic F-127-coated tungsten diselenide (WSe<sub>2</sub> @F127) nanozymes are developed by simple liquid-phase exfoliation. The abundant valence transitions of elemental selenium (Se<sup>2-</sup> /Se<sup>4+</sup> ) and tungsten (W<sup>4+</sup> /W<sup>6+</sup> ) enable the obtained WSe<sub>2</sub> @F127 nanozymes to eliminate reactive oxygen/nitrogen species. In addition, the released tungsten ions are capable of inhibiting the proliferation of Escherichia coli. In a model of dextran sodium sulfate-induced colitis, WSe<sub>2</sub> @F127 nanozymes modulate the gut microbiota by increasing the abundance of bacteria S24-7 and significantly reducing the abundance of Enterobacteriaceae. Moreover, WSe<sub>2</sub> @F127 nanozymes inhibit T-cell differentiation and improve intestinal immune barrier function in a model of Crohn's disease. The WSe<sub>2</sub> @F127 nanozymes effectively alleviate IBD by reducing oxidative stress damage, modulating intestinal microbial populations, and remodeling the immune barrier.
Medical subject headings
- Gastrointestinal Microbiome
- Inflammatory Bowel Diseases
- Polyethylenes
- Polypropylenes